CYP3A4 and breast carcinoma: inactivates cyclophosphamide via conversion to dechloroethylcyclophosphamide, and breast cancer patients showed that many CYP3A4 variant polymorphisms are more prevalent in African Americans compared with Caucasians.55, 73